Trial Profile
SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms SOLAR; SOLAR-1
- Sponsors Novartis; Novartis Pharmaceuticals
- 17 Nov 2023 Results evaluating the cost-effectiveness of alpelisib plus fulvestrant in patients with PIK3CA-mutated, HR+/HER2- ABC in the USA , by deriving data from SOLAR-1 , published in the Clinical Drug Investigation
- 28 Jun 2023 Status changed from active, no longer recruiting to completed.
- 09 May 2023 Planned End Date changed from 8 Jun 2023 to 12 Jun 2023.